Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) tigolasheng tablet was approved to carry out clinical trials for new indications

Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) announced that Shandong Luoxin, a subsidiary of the company, received the notice of approval for clinical trial of tigolasheng tablets for Helicobacter pylori infection issued by the State Drug Administration. The indication for this clinical trial is to eradicate adult Helicobacter pylori infection in combination with appropriate antimicrobial therapy.